Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood‐donor screening (Q46126583)

19 December 2017

title

Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening (English)

1 reference

19 December 2017

Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood‐donor screening (English)

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

13 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

13 March 2024

11

Michael P Busch

1 reference

19 December 2017

2

Susan L Stramer

1 reference

19 December 2017

1

Leslie H Tobler

1 reference

19 December 2017

Jaye P Brodsky

8

object named as

Jaye P Brodsky

1 reference

19 December 2017

author name string

Stephen R. Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507279

13 March 2024

Barbara L. Masecar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507279

13 March 2024

Jon E. Peterson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507279

13 March 2024

E. Anne Davis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507279

13 March 2024

William E. Andrews

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507279

13 March 2024

Steven H. Kleinman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507279

13 March 2024

Bruce H. Phelps

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14507279

13 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14507279

13 March 2024

publication date

1 October 2003

1 reference

19 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1537-2995.2003.00521.x

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1537-2995.2003.00521.x

13 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

13 March 2024

1 reference

19 December 2017

volume

43

1 reference

19 December 2017

issue

10

1 reference

19 December 2017

page(s)

1452-1459

1 reference

19 December 2017

International application of the incidence rate/window period model.

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein. Multicentre Hemodialysis Cohort Study on Viral Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00521.X

A twelve year natural history of hepatitis C virus infection in hemodialyzed patients

21 January 2018

6

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Outcome of HCV infection after renal transplantation

13 March 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma

13 March 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Frequency and characteristics of post-transfusion hepatitis in Greece with emphasis on hepatitis C: comparing second- and third-generation assays

13 March 2024

19

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay

13 March 2024

26

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.

13 March 2024

28

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Significance of NS3 and NS5 antigens in screening for HCV antibody.

13 March 2024

29

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Evaluation of third-generation screening and confirmatory assays for HCV antibodies

13 March 2024

31

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

Significance of NS3 and NS5 antigens in screening for HCV antibody.

13 March 2024

33

1 reference

https://api.crossref.org/works/10.1046/J.1537-2995.2003.00521.X

13 March 2024

Identifiers

1 reference

19 December 2017

1 reference

19 December 2017